Press Release from HemoCath

HemoCath Appoints Industry Veteran Dr. Melissa Fusari as the Chief Clinical Officer

AUSTIN, TX  – MAY 8, 2024 – HemoCath Ltd., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the appointment of Dr. Melissa Fusari, a seasoned clinical and industry expert, as the Chief Clinical Officer (CCO).

"We welcome Melissa's clinical and industry experience and leadership as HemoCath prepares for US commercial entry and advances towards our clinical milestones," said Eric Caron, CEO of HemoCath. ”Melissa has over 30 years of clinical and industry experience with a proven record of providing medical and scientific leadership expertise to leading medical technology companies globally.” 

Dr. Melissa Fusari is a cardiovascular surgeon trained in interventional cardiology, specializing in transcatheter artificial heart valves. From 2012 to 2023, she was a key contributor at Edwards Lifesciences in multiple roles: Physician Proctor for TAVR & TMVR supporting pre-clinical research and clinical trials, providing clinical insight into global market development, strategic planning, R&D, quality and sales. Dr. Fusari served as a Cardiovascular Surgeon and the Chief of Cardiovascular Endovascular Surgery at Gavazzeni hospital and Monzino Heart Center in Italy from 1999 to 2012. Dr. Fusari is the author of numerous peer-reviewed medical journal articles.

“Individually, the HemoCath pulmonary artery (PA) catheter presents significant advantages to clinicians when compared to current PA catheters,” stated Dr. Fusari. “Combined with the Luc AI Cloud, the HemoCath Platform represents a groundbreaking advancement in tailoring cardiac care to suit the unique needs of every patient. Moreover, in the near future, the Platform will provide an invaluable database of precise clinical data for researchers and the HF industry.”

About HemoCath
HemoCath pioneers advancements at the crossroads of Medtech and Digital Health, aiming to enhance care for individuals with heart failure (HF). The versatile and scalable HemoCath™ AI Platform enables proactive AI-data-driven management of patients with acute HF from diagnosis to treatment and monitoring for all hospital heart procedures. The user-friendly integrated Platform includes the HemoCath™ PA catheter securely connected to the Luc™ AI Cloud to continuously measure and monitor PAP & CVP, the leading indicators of heart congestion, allowing early targeted therapy. The vital health information remains easily available to the managing clinician, supporting optimal dosing of guideline-directed medical therapy (GDMT) across the entire spectrum of HF. Several clinical trials provide clinical evidence of a significant improvement in cardiac care and reduction in hospital stay ​with PAP-guided HF management. Learn more at www.hemocath.com 



The HemoCath™ Pulmonary Artery Catheter System is an investigational device and is not currently approved for clinical use in any geography. 

Cautionary Statement Regarding Forward-Looking Statements
This press release may contain predictions, estimates, or other information that might be considered forward-looking statements. Such forward-looking statements are not a guarantee of future performance.